The prospective, double-blind, randomized controlled trial (RCT) enrolled 244 patients to evaluate the Butterfly Prostatic Retraction Device, a minimally invasive, reversible implant that mechanically ...

Benign Prostatic Hyperplasia (BPH), or enlarged prostate, is a common condition affecting millions of men, especially those over 50. It can lead to uncomfortable urinary symptoms and significantly ...

NEW TECHNOLOGY: The new HYDROS™ Robotic System is the next-generation platform to treat men suffering from benign prostatic hyperplasia. (Submitted Photo) THOMASVILLE — Archbold is now offering ...

DUBLIN, Aug. 25, 2025 /PRNewswire/ -- ProVerum Limited, the developer of the ProVee® System for BPH, a minimally invasive solution for treating benign prostatic hyperplasia (BPH), announced today the ...

New London — A walnut-size gland that tends to grow, eventually causing trouble for most men, has a new nemesis at Lawrence + Memorial Hospital: robot-assisted Aquablation therapy. Dr. Timothy Tran, ...

IRVINE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NYMXF) [OTC Markets – NYMXF] (the “Company”) is pleased to announce today that a new formal submission has been ...

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...

Drug Used for Enlarged Prostate Tied to High Glaucoma Risk The use of alpha-blockers for benign prostatic hyperplasia is tied to an increased risk of developing acute angle-closure glaucoma, a study ...

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...

HASBROUCK HEIGHTS, N.J., April 10, 2018 (GLOBE NEWSWIRE) -- A new online published commentary about Nymox’s (NASDAQ:NYMX) Fexapotide 2018 clinical trial results publication in World Journal of Urology ...